Q-omics provides the consensus-scored CXCL5 profile across patient tissues and cancer cell-line models. CXCL5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CXCL5 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, CXCL5 RNA expression shows 18,713 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where CXCL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CXCL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CXCL5 survival associations across molecular data types. CXCL5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CXCL5 RNA expression–survival associations across cancer types. High CXCL5 expression shows unfavorable associations in KIRC, CESC, UVM, GBM, LIHC and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CXCL5 RNA expression.
This table summarizes CXCL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CXCL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CXCL5 shows lower tumor expression in BRCA, KICH and LUSC and higher tumor expression in COAD, KIRC and THCA. The COAD box plot shows higher CXCL5 RNA expression in tumor versus normal tissue (log2 FC = +3.312, t-test p < 0.001).
This table shows molecular features associated with CXCL5 in patient tissues and cancer cell lines. In patient samples, CXCL5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CXCL5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
